GLP-1s across Singapore, Thailand & Indonesia

TL;DR

• Three regulators, one consistent message - these are registered, prescription-only medicines, and grey-market supply is illegal or unsafe in all three markets.
• Singapore's HSA approved Wegovy for weight management in 2023, with Mounjaro's weight-management indication following in 2025; eligibility generally starts at age 21 with BMI ≥30, or ≥27 plus a comorbidity.
• Wegovy also gained a Singapore indication in 2025 to reduce major adverse cardiovascular events in eligible patients.
• Thailand registered Wegovy in 2023, and the Thai FDA has since tightened controls on injectable GLP-1s specifically because of their misuse as cosmetic "weight-loss pens."
• Indonesia's BPOM has approved semaglutide and tirzepatide for import and prescription by licensed doctors through BPOM-registered pharmacies.
• Medical tourism is legitimate but only with a plan - continuity of care, cold-chain handling and source verification are what fail when it is done carelessly.

Educational content, not medical advice, and not a substitute for each country's regulator. No doses or protocols appear.

---

Beyond Malaysia, the three markets Vivre's expansion touches - Singapore, Thailand and Indonesia - have each registered GLP-1 medicines and each require a prescription. The details differ, but the principle is identical everywhere: regulator-registered product, licensed prescriber, proper assessment. Here's the market-by-market picture.

Singapore (HSA)

Singapore's Health Sciences Authority (HSA) approved Wegovy for weight management back in 2023, with prescribing scaling up from late 2025; Mounjaro's weight-management indication followed in 2025 (for adults with BMI ≥30, or ≥27 with a weight-related comorbidity). Ozempic and Rybelsus are approved for type 2 diabetes. In a notable 2025 development, Wegovy also gained an indication to reduce major adverse cardiovascular events in eligible patients.

All semaglutide and tirzepatide products in Singapore are prescription-only medicines (POM) - they cannot be bought over the counter, and purchasing from unverified online or overseas sources is illegal. The HSA has actively removed unauthorised listings from online marketplaces. Eligibility generally starts at age 21, BMI ≥30 or ≥27 with a comorbidity.

Thailand (Thai FDA)

Thailand registered Wegovy in 2023, and the major brands (Ozempic, Wegovy, Mounjaro, Saxenda, Rybelsus) are available through licensed clinics. Access requires a prescription and an in-person assessment. Notably, the Thai FDA has tightened controls on injectable GLP-1 products specifically because of their misuse as casual cosmetic "weight-loss pens" - a reminder that these are medical treatments, not lifestyle accessories. Bangkok has a large, visible clinic market, which makes the verify-the-source rule especially important.

Indonesia (BPOM)

Indonesia's BPOM has approved semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) for import and prescription when prescribed by a licensed doctor for appropriate clinical indications, sourced through BPOM-registered pharmacies. As elsewhere, GLP-1 for weight management is generally reserved for BMI >30, or >27 with metabolic comorbidities - not cosmetic use at a normal weight. Reputable Indonesian providers explicitly reject compounded or "research-chemical" GLP-1 sources.

Medical tourism: a real option, with real caveats

Bangkok and Bali in particular have become hubs for doctor-supervised metabolic and longevity treatment, and for many travellers that's a legitimate, well-run route. The caveats are worth stating plainly:

• Continuity of care. A GLP-1 is an ongoing treatment; starting one abroad without a plan for monitoring and refills at home is a poor idea.
• Cold chain. Injectable GLP-1s must stay temperature-controlled - carrying them across borders needs planning.
• Source verification. The same rule applies abroad: regulator-registered product, licensed prescriber, no compounded shortcuts.

Done properly - a reputable clinic, verified product, and a monitoring plan - it can work well. Done carelessly, it inherits every grey-market risk plus a border.

The bottom line - and where to start

Across Singapore, Thailand and Indonesia, the regulatory reality rhymes with Malaysia's: these are registered, prescription-only medicines, and the safe path is a licensed prescriber and a verified product. Whether you're local or travelling, the deciding factor isn't geography - it's whether there's genuine oversight and a supply you can trust.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

Frequently asked questions

Is Wegovy available in Singapore? Yes - the HSA approved Wegovy for weight management in 2023, and it's actively prescribed to eligible patients (generally BMI ≥30, or ≥27 with a comorbidity, age 21+). It's a prescription-only medicine; buying it from unverified sources is illegal, and the HSA has removed unauthorised online listings.

Can I get GLP-1s in Thailand as a tourist? Yes, through licensed clinics with a prescription and in-person assessment - Bangkok has a large clinic market. The Thai FDA has tightened controls on injectable GLP-1s misused cosmetically, so verify the clinic, the product, and a plan for monitoring and continuity when you return home.

Are GLP-1s BPOM-approved in Indonesia? Yes - semaglutide and tirzepatide are BPOM-approved for import and prescription through licensed doctors and registered pharmacies. Reputable providers source only BPOM-registered product and avoid compounded or research-chemical versions.

Related reading

• GLP-1s in Malaysia: NPRA rules & how to verify · GLP-1 access in Vietnam and the Philippines · The complete GLP-1 guide · New weight-loss drugs 2026–2027
• Part of GLP-1s & Peptides in Southeast Asia

---

Educational content, not medical advice, and not a substitute for official regulator guidance. Verify current status with HSA (Singapore), the Thai FDA, or BPOM (Indonesia). GLP-1s are prescription medicines requiring individual assessment. Claims for the Malaysian market are subject to MAB requirements.

References

• Singapore HSA: Wegovy approved 2023 (prescribing scaled from late 2025), Mounjaro weight-management approval 2025 (BMI ≥30 or ≥27 + comorbidity, age 21+), Ozempic/Rybelsus for T2D, Wegovy CV-risk indication 2025; all POM; HSA removal of unauthorised listings (reported Nov 2025). · Thailand Thai FDA: Wegovy approved 2023; brands available by prescription with in-person assessment; tightened controls on injectable cosmetic misuse. · Indonesia BPOM: approved import/prescription of semaglutide and tirzepatide via licensed doctors/registered pharmacies; BMI >30 or >27 + comorbidity. · Medical-tourism considerations: continuity of care, cold chain, source verification.